doi:10.4103/jehp.jehp_109_15
By enabling sustained release, targeted delivery, and improved bioavailability, these platforms offer promising strategies for enhancing therapeutic outcomes in metabolic diseases
Since this is a new delivery platform of existing drugs rather than a new drug, the regulatory bodies in many jurisdictions typically have alternative, shorter approval pathways available to drug sponsors that do not require the standard Phase I-III clinical trials for a new drug application
Now, the Danish pharma giant could be onto something bigger as it has hinted that Wegovy could even reduce the risk of heart attack in some patients
Patients taking GLP-1 medications in combination with insulin or sulfonylureas face higher risk
Reduced appetite helps to curb hunger, so you can start feeling full sooner